A contract in Japan for DMS Wellness
A contract in Japan for DMS WellnessLATEST
FACT
DMS announced DMS Wellness has signed a contract with Japanese Ritsubi for the supply of a minimum 400 Cellis devices over the next three years.
ANALYSIS
As a reminder, Cellis is the group’s cellulite and lymphatic drainage solution, part of the Wellness division. The agreement should lead to 400 deliveries in the next three years. This is undoubtedly good news, with the first revenues of the Wellness division now at reach, as we wrote on 17 April and a similar agreement with Chinese JCCO. However, as we also wrote at that time, this does not hide the fact that FY17 revenues were disappointing (see our Latest dated 4 February 2017) and that the FY17 results due on 30 April are very likely to be weak. We are also not too sure why DMS does not, contrary to what was the case in the previous agreement with JCCO, give an estimate of the achievable turnover with this new distribution agreement. In any case, the news is still positive and comes at a time when DMS is finding it difficult to grow (FY17 sales down 9% on a comparable basis). Again as we stated earlier, let’s hope that this new inroad into side-segments (on top of the core radiology/bone densitometry businesses) enables the group to post a stronger top-line growth for the years to come.
IMPACT
We will not change our forecasts at this stage, since the FY17 results are due in two weeks (with a likely disappointment as earlier indicated) and also since we lack details on the contract to translate it into estimates.
DIAGNOSTIC MEDICAL SYSTEMS SA, (formerly known as DMS), is a France-based company, which together with its subsidiaries, designs, produces and markets medical imagery devices dedicated to conventional and digital radiology as well as bone densitometry. The Company manufactures a range of products for bone densitometry examination, including the ultrasound imaging system UBIS 5000, Challenger Envision, Stratos dR and Stratos. In the radiology sector, its products include Baccara dRF 43, EOL, Platinum and Da Vinci solutions, among others. In addition, it offers such products as scanners, transcranial Doppler, and Giotto Image mammography system. The Company operates several direct subsidiaries, AXS Medical, Apelem SAS, which manufactures radiology equipment, Medilink SARL, which produces Doppler and bone densitometry devices, Apelem SA, based in Spain, Alpha MOS based in France and one indirect subsidiary, SA Apelem and one indirect affiliated company, Spectrap.
AlphaValue Corporate Services capitalise on the research and credit analysis expertise deployed by AlphaValue with major institutional investors at European level over the past nine years. The proprietary tools and processes enabling AlphaValue Corporate Services to establish a valuation and/or a credit risk assessment are identical to those used by AlphaValue to the benefit of its institutional clients. The only difference is the recognition that a company evaluation cannot be dissociated from the fact that the latter is paying for the service (AlphaValue Corporate Services), as opposed to the investor footing the bill (AlphaValue). AlphaValue’s research tools are characterised by the transparency of the valuation methodologies, their responsiveness to market data and by nine years’ experience of a universe numbering more than 450 European companies. Through its coverage and sector exhaustiveness, AlphaValue ranks alongside the major research houses in Europe and constitutes the only new entrant to the European space in the past decade. This significant presence is reflected in an unrivalled distribution capability via platforms commonly adopted by investors to access research: Factset, Bloomberg, Capital IQ and the numerous websites. AlphaValue is one the largest research contributors to these platforms, to the benefit of AlphaValue Corporate Services issuer clients. The AlphaValue Corporate Services analysts are AlphaValue’s sector specialists. Their robust knowledge of the business models in their sectors enables the rapid generation of incisive, relevant research and advantageous interaction with the management teams.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.